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A B S T R A C T   
Introduction: Placental Protein 1 (PP1), PP8, and PP22 were isolated from the placenta. Herein, we aimed to 
identify PP1, PP8, and PP22 proteins and their placental and trophoblastic expression patterns to reveal potential 
involvement in pregnancy complications. 
Methods: We analyzed PP1, PP8, and PP22 proteins with LC-MS. We compared the placental behaviors of PP1, 
PP8, and PP22 to the predominantly placenta-expressed PP5/TFPI-2. Placenta-specificity scores were generated 
from microarray data. Trophoblasts were isolated from healthy placentas and differentiated; total RNA was 
isolated and subjected to microarray analysis. We assigned the placentas to the following groups: preterm 
controls, early-onset preeclampsia, early-onset preeclampsia with HELLP syndrome, term controls, and late-onset 
preeclampsia. After histopathologic examination, placentas were used for tissue microarray construction, im-
munostaining with anti-PP1, anti-PP5, anti-PP8, or anti-PP22 antibodies, and immunoscoring. 
Results: PP1, PP8, and PP22 were identified as ‘nicotinate-nucleotide pyrophosphorylase’, ‘serpin B6’, and 
‘protein disulfide-isomerase’, respectively. Genes encoding PP1, PP8, and PP22 are not predominantly placenta- 
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expressed, in contrast with PP5. PP1, PP8, and PP22 mRNA expression levels did not increase during trophoblast 
differentiation, in contrast with PP5. PP1, PP8, and PP22 immunostaining were detected primarily in tropho-
blasts, while PP5 expression was restricted to the syncytiotrophoblast. The PP1 immunoscore was higher in late- 
onset preeclampsia, while the PP5 immunoscore was higher in early-onset preeclampsia. 
Discussion: PP1, PP8, and PP22 are expressed primarily in trophoblasts but do not have trophoblast-specific 
regulation or functions. The distinct dysregulation of PP1 and PP5 expression in either late-onset or early- 
onset preeclampsia reflects different pathophysiological pathways in these preeclampsia subsets.   
1. Introduction 
Preeclampsia (PE) is one of the most severe obstetrical syndromes 
that leads to maternal and perinatal morbidity and mortality [1,2]. 
According to gestational age at the time of the clinical presentation of 
the disease, preeclampsia can be subdivided into early-onset (<34 weeks 
of gestation) and late-onset (≥34 weeks of gestation) subforms [2,3]. 
Early-onset preeclampsia is the more severe form, affecting the placenta 
and fetus, and it is more often associated with HELLP (Hemolysis, 
Elevated Liver enzymes, and Low Platelet count) syndrome, intrauterine 
growth restriction (IUGR) or the delivery of a small-for-gestational-age 
(SGA) neonate than late-onset preeclampsia [2,4]. 
Several mechanisms contribute to the development of preeclampsia. 
In early-onset preeclampsia, abnormal placentation and defective spiral 
artery remodeling by invasive trophoblasts are associated with placental 
lesions consistent with maternal vascular malperfusion (MVMP) and 
oxidative stress, ultimately leading to the release of syncytiotrophoblast 
debris and pro-inflammatory and anti-angiogenic molecules into the 
maternal circulation [5–18]. Compared to the physiological state at the 
maternal-fetal interface [19,20], these conditions will result in endo-
thelial dysfunction, cardiovascular changes and an exaggerated 
maternal systemic inflammatory response, which also includes leuko-
cyte and complement activation as well as thrombin generation [7,9, 
21–25]. Although its complex pathophysiology and triggering condi-
tions are still not fully understood, it is evident that the placenta plays an 
important role in the development of early-onset preeclampsia, further 
substantiated by the fact that the only current, effective therapy for 
preeclampsia is the delivery of the placenta [1]. 
Uteroplacental vascular insufficiency, placental lesions consistent 
with MVMP, an anti-angiogenic state and increased shedding of syncy-
tiotrophoblast microparticles are less characteristic of late-onset pre-
eclampsia [16,26]. Indeed, this late-onset subform may be induced by 
stress factors distinct from ischemic stress of the placenta [27]. Based on 
these observations, it was proposed that early-onset preeclampsia is 
principally a placental disease, while late-onset preeclampsia is pre-
dominantly a maternal disease. For example, pro-inflammatory and 
metabolic conditions in various maternal diseases, e.g., diabetes melli-
tus, kidney disease, and autoimmune diseases, may lead to the devel-
opment of late-onset preeclampsia [28,29]. Nevertheless, our recent 
study suggested that these predisposing maternal disease conditions also 
eventually lead to placental malfunction in late-onset preeclampsia 
[16]. Therefore, there is an increased interest in the identification of 
placental factors involved in the pathogenesis of early- or late-onset 
subforms of preeclampsia in order to develop new diagnostic and ther-
apeutic tools for this deadly syndrome. 
Placental proteins (PPs) may play a role in the pathogenesis of these 
placental diseases [13,16,30–34]. Placental Protein 1 (PP1), PP8, and 
PP22 were originally isolated from the human placenta and character-
ized by Hans Bohn and his colleagues in the 1970’s, among the 26 sol-
uble placental proteins they isolated and named sequentially [35,36]. 
Data on their physico-chemical properties and expression patterns in 
human tissues and body fluids were reported; however, nothing has 
been revealed on their identity, functional properties, or placental 
expression in either healthy or diseased conditions in pregnancy [36]. 
During our earlier studies, we isolated and sequenced the cDNAs for a set 
of placental proteins isolated by Dr. Bohn and explored their structure 
and function as well as placental and maternal expression in pregnancy 
[37–44]. 
Herein, we aimed to identify PP1, PP8, and PP22 amino acid se-
quences, expression patterns in the villous placenta in healthy and 
diseased conditions, and villous trophoblastic differentiation in order to 
reveal their involvement in severe pregnancy complications of placental 
origin. 
2. Materials and methods 
2.1. Protein identification with liquid chromatography–tandem mass 
spectrometry 
Lyophilized PP1, PP8, and PP22 protein samples (the kind gift from 
Dr. Hans Bohn, Behringwerke AG, Marburg-Lahn, Germany) were 
analyzed at the Biological Research Centre of the Hungarian Academy of 
Sciences (Szeged, Hungary). Briefly, samples were dissolved in guani-
dine HCl, disulfide bridges were reduced with dithiothreitol, and the 
resulting free sulfhydryls were alkylated with iodoacetamide. Digestion 
with trypsin (Promega, Madison, WI, USA) proceeded at 37 ◦C for 4 h. 
Sample clean-up was performed using C18 pipette tips. 
Samples were analyzed on an Eldex nanoHPLC system (Eldex Labo-
ratories, Inc., Napa, CA, USA) online coupled to a 3D ion trap mass 
spectrometer (MS) (LCQ Fleet, Thermo Fisher Scientific, Waltham, MA, 
USA) in “triple play” data-dependent acquisition mode, where MS ac-
quisitions were followed by collision-induced dissociation (CID) ana-
lyses on computer-selected multiply charged ions. The HPLC conditions 
were as follows: 0–10 min: 5% of solvent B followed by a linear gradient 
of 5–60% solvent B in the next 35 min (flow rate was 300 nL/min, sol-
vent A was 0.1% formic acid in water, and solvent B was 0.1% formic 
acid in acetonitrile). A reversed phase C18 nano column was used 
(Waters Atlantis C18 Column, 3 μm particle size, 75 μm × 100 mm, 
Waters Corporation, Milford, MA, USA). Raw data were converted to 
mascot generic file format using Mascot Distiller software v2.1.1.0. 
(Matrix Science Inc, London, UK) and searched against the human en-
tries of the NCBInr 20080718 protein database (186,569 sequences were 
searched) on an in-house Mascot server (v2.2.04) using standard pa-
rameters. (Searching parameters: trypsin was specified as an enzyme 
allowing only fully specific cleavages with maximum two missed 
cleavage sites, carbamidomethylation of Cys was set as fixed; and 
acetylation of protein N-termini, pyroglutamic acid formation of peptide 
N-terminal Gln, and oxidation of Met were set as variable modifications. 
Mass tolerance was set to ±0.6 Da and ±1 Da for the precursor and the 
fragment ions, respectively.) Acceptance parameters were minimum two 
unique peptides per protein (Mascot peptide score ≥40, p <0.05). In the 
manuscript hereafter proteins are referred to as their “Uniprot names” 
from Uniprot database. 
2.2. Primary villous trophoblast differentiation 
As described in Szilagyi et al. [45], placentas (n = 6) were collected 
at the Perinatology Research Branch (NICHD/NIH/DHHS, Detroit, MI, 
USA) from normal pregnant women at term who delivered an 
appropriate-for-gestational-age (AGA) neonate by Cesarean section. 
Villous cytotrophoblasts were isolated from these placentas utilizing the 
modified method of Kliman et al. [46]. Briefly, 100 g of villous tissues 
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were cut and rinsed in PBS and then digested with Trypsin (0.25%; Life 
Technologies, Grand Island, NY, USA) and DNAse I (60 U/mL; Sig-
ma-Aldrich) for 90 min at 37 ◦C. Dispersed cells were filtered through 
Falcon nylon mesh cell strainers (100 μm, BD Biosciences, San Jose, CA, 
USA). Erythrocytes were lysed with 5 mL of NH4Cl solution (Stemcell 
Technologies, Vancouver, BC, Canada), and then washed, and the 
resuspended cells were layered over 20–50% Percoll gradients and 
centrifuged for 20 min at 1,200g. Bands containing trophoblasts were 
collected and non-trophoblastic cells were excluded by negative selec-
tion using anti-CD9 (20 μg/mL) and anti-CD14 (20 μg/mL) mouse 
monoclonal antibodies (R&D Systems, Minneapolis, MN, USA), MACS 
anti-mouse IgG microbeads (Miltenyi Biotec, Auburn, CA, USA), and MS 
columns (Miltenyi Biotec). Primary villous trophoblasts were plated on a 
collagen-coated 12-well plate (BD Biosciences; 3 × 106 cells/well) in 
Iscove’s modified Dulbecco’s medium (IMDM; Life Technologies), sup-
plemented with 10% fetal bovine serum (FBS) and 1% pen-
icillin/streptomycin (P/S). Primary trophoblasts were kept in IMDM 
containing 5% non-pregnant human serum (SeraCare, Milford, MA, 
USA) and 1% P/S. The medium was replenished every 24 h, and cells 
were harvested for total RNA every 24 h between Day 0 and Day 7. 
2.3. Total RNA isolation and microarray 
As described in Szilagyi et al. [45], total RNA was isolated from 
primary villous trophoblasts from Day 0 to Day 7 of differentiation with 
TRIzol reagent (Life Technologies) and the RNeasy kit (QIAGEN, Dus-
seldorf, Germany), according to the manufacturers’ recommendations. 
The 28S/18S ratios and the RNA integrity numbers were assessed using 
an Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, 
USA); RNA concentrations were measured with NanoDrop 1000 
(Thermo Fisher Scientific). Five hundred micrograms of DNase-treated 
RNA samples (n = 3) were amplified and biotin-labeled with the Illu-
mina TotalPrep RNA Amplification Kit (Ambion, LifeTechnologies, 
Foster City, CA, USA), and then the labeled cRNAs were hybridized to 
HumanHT-12v4 Expression BeadChips (Illumina Inc., San Diego, CA, 
USA). Subsequently, BeadChips were imaged using an Illumina Bea-
dArray Reader, and raw data were obtained with Illumina BeadStudio 
Software V.3.4.0. 
2.4. Clinical samples and definitions 
The study was approved by the Health Science Board of Hungary 
(ETT-TUKEB approval number: 22–164/2007-1018EKU). Samples were 
collected after written informed consent was obtained from all women 
enrolled into the study. Specimens and data were stored anonymously. 
All placental samples were obtained from Cesarean sections, and 
maternal blood specimens were collected from the same women at de-
livery at the First Department of Obstetrics and Gynecology, Semmel-
weis University (Budapest, Hungary). Pregnancies were determined 
within 8–12 weeks of gestation according to first-trimester ultrasound 
scans. Cases with multiple births, fetal congenital abnormalities or 
chromosomal disorders were excluded from this study, after the enrolled 
women were classified into the following groups: 1) early-onset pre-
eclampsia (n = 7); 2) early-onset preeclampsia with HELLP syndrome (n 
= 8); 3) late-onset preeclampsia (n = 8); 4) preterm controls (n = 5); and 
5) term controls (n = 9) (Table 1). 
Term controls delivered an AGA neonate without medical or 
obstetrical complications. Preterm control placentas were obtained from 
women who had episode of preterm labor leading to preterm birth 
without clinical or histological signs of chorioamnionitis. Preterm con-
trols had no other medical complications and delivered an AGA neonate 
[47]. 
Preeclampsia was defined by the presence of new-onset hypertension 
(systolic/diastolic blood pressure ≥140/90 mmHg, respectively, 
measured at two time points, more than 4 h apart) and proteinuria (24 h 
urine protein ≥300 mg, 2 dipsticks more than 4 h apart ≥1+ or 1 
dipstick ≥2+ protein in random urine specimens) that developed after 
the 20th week of gestation [1,2]. HELLP syndrome was characterized by 
hemolysis (serum LDH >600 IU/L; bilirubin >1.2 mg/dL; presence of 
schistocytes in peripheral blood), elevated liver enzymes (serum ALT 
and/or AST >70IU/L), and thrombocytopenia (platelet count <100,000 
/mm3) [4,48]. All women diagnosed with preeclampsia received anti-
hypertensive treatment before surgery. Cesarean section was performed 
in all cases due to severe, conservatively untreatable maternal symptoms 
and/or non-reassuring fetal condition as well as in all controls due to 
previous Cesarean section or malpresentation. 
2.5. Sample collection and histopathologic examination 
Immediately after delivery, the placentas were examined according 
to a standard perinatal pathologic protocol that describes the topog-
raphy and size of macroscopic lesions [49]. Six-eight tissue samples 
were taken from central and peripheral cotyledons and the maternal side 
of the placenta, fixed in formalin and embedded in paraffin (FFPE) or 
were deep-frozen and stored at − 80 ◦C. We completed tissue sampling 
and processing within one half-hour after Cesarean delivery of all 
Table 1 
Demographic and clinical characteristics.  
Groups Preterm control Early-onset preeclampsia Term control Late-onset preeclampsia 
without HELLP sy. with HELLP sy. 
Number of casesa 5 7 8 9 8 
Maternal age (years)b 31.6 (31.1–34.3) 34.0 (27.6–35) 29.4 (27.1–30.1) 30.8 (30.1–34.2) 31.3 (26–34.2) 
Gestational age at delivery (weeks)b 31.7 (31–34) 32.6 (31.2–34.4) 29.4 (28.4–32.3) 38.9 (38.7–39.7) 37.4 (36.8–38)# 
Systolic blood pressure (mmHg)b 120 (120–133) 160 (156.3–160)* 165 (147.5–170)* 130 (125–135) 156.5 (150.8–167.5)## 
Diastolic blood pressure (mmHg)b 80 (70–80) 100 (100-100)* 100 (97.5–110)* 80 (78–85) 95 (90–100)## 
Maternal BMI (kg/m2)b 23.4 (20.1–24.6) 24.4 (23.4–25.2) 24.7 (21.3–26.8) 26.7 (23.1–28) 21.9 (19.6–23.1) 
Birth weight (g)b 1,990 (910–2,210) 1,100 (1,010–1,280) 965 (885–1,512.5) 3,470 (3,400–4,030) 2,955 (2,587.5–3,162.5)## 
Placental weight (g)b 294 (290–301) 217 (211–227)* 185 (141–279)* 518 (481–650) 470 (431–486)# 
MVMP scoreb 1 (0–2) 8 (5–8.5)* 6.5 (5–8)** 2 (1–3) 2 (1.75–4.5) 
Proteinuriac 0 100** 100** 0 100## 
All women were Caucasian. 
MVMP: maternal vascular malperfusion. 
**p <0.01. 
*p <0.05 compared to gestational-age-matched preterm controls. 
##p <0.01. 
#p <0.05 compared to gestational-age-matched term controls. 
a Values are presented as number. 
b Values are presented as median (interquartile (IQR) range). 
c Values are presented as percentage. 
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placentas to minimize sampling and sample processing bias according to 
international standards [50]. 
For microscopic examinations, 4 μm sections were cut from FFPE 
tissue blocks and mounted on SuperFrost/Plus slides (Gerhard Menzel 
GmbH, Braunschweig, Germany). After deparaffinization, slides were 
rehydrated, stained with hematoxylin-eosin, and evaluated in 10 
randomly selected microscopic fields. Macroscopic and microscopic le-
sions were defined according to published criteria [49,51,52]. Histo-
pathological signs of MVMP were summarized and a composite MVMP 
score was generated for each placenta, as described earlier [16,33]. 
2.6. Tissue microarrays and immunostaining 
FFPE tissue sections were stained with hematoxylin-eosin for histo-
pathologic evaluation at the First Department of Pathology and Exper-
imental Cancer Research, Semmelweis University (Budapest, Hungary). 
Representative areas were selected for the construction of tissue 
microarrays (TMAs), as described earlier [13,15,31], which contained 2 
mm cores in diameter from five tissue blocks from each of the cases (n =
37). 
After inhibition of endogenous peroxidases with 10% H2O2 in 
methanol for 20 min at room temperature, antigen retrieval was carried 
out by incubating slides at 100 ◦C in TRS (10 mM Tris; 1 mM EDTA; 
0.05% Tween 20; pH = 9; 3 min). Immunostaining was performed using 
the NovoLink Polymer Detection System (Peroxidase/DAB+, Rabbit, 
Novocastra Laboratories, Newcastle, UK). Unspecific antibody binding 
was blocked for 10 min at room temperature using Novocastra Protein 
Block. Slides were incubated with anti-PP1, anti-PP8, anti-PP22, and 
anti-PP5 antibodies overnight at 4 ◦C as described in Suppl. Table 1. 
Subsequently, the NovoLink Polymer was applied for 30 min at room 
temperature. The primary antibody binding was visualized using DAB, 
and counterstained with hematoxylin. Primary antibodies were omitted 
for negative controls. 
2.7. Evaluation of the immunostainings 
Placental TMAs immunostained for PPs were digitally scanned by a 
high-resolution bright field slide scanner (Pannoramic Scan, 3DHistech 
Ltd., Budapest, Hungary). Immunostainings on virtual slides were 
evaluated by two examiners blinded to the clinical information using the 
Pannoramic Viewer 1.15.4 (3DHistech Ltd.). At least 25 terminal or 
intermediate villi (diameter of 20–150 μm) were scored semi- 
quantitatively in each core, using a scoring system modified from that 
previously published [30]. The intensity of the immunoscores was 
graded as 0-3+. The average intensity was determined for each core as 
the representative data for that core. By averaging immunoscores of the 
cores, the overall intensity score was assigned to each patient group. 
2.8. Data analysis 
Demographic data were analyzed using Microsoft Excel v.2016 
(Microsoft Corp., Redmond, WA, USA). Comparisons among the groups 
were performed using Chi-square and Fisher’s exact tests for pro-
portions, Kruskal–Wallis and Mann–Whitney tests for non-normally 
distributed continuous variables, and the Student’s t-test for normally 
distributed continuous variables. Statistical significance was considered 
as p <0.05. 
The placenta-specificity score (expression level in the placenta/me-
dian expression level in 78 other tissues and cell sources) of placental 
proteins was determined from BioGPS microarray data similar to that 
described in Than et al. [16]. Herein, we considered a gene to be pre-
dominantly expressed by the placenta if its highest expression level was 
found to be in the placenta and its placental expression was ≥6-fold 
higher than its median expression values in 78 other tissues and cell 
sources. 
The expression changes of genes encoding for these placental 
proteins during trophoblast differentiation were determined from our 
microarray data (GEO accession number: GSE130339). Microarray data 
analysis of villous trophoblastic gene expression was performed in the R 
statistical language and environment as described in Than et al. [16] and 
Szilagyi et al. [45]. 
3. Results 
3.1. Demographic and clinical data 
Demographic and clinical characteristics are displayed in Table 1. 
Systolic and diastolic blood pressures were higher in all disease groups 
than in the control groups. Proteinuria was detected in all cases but not 
in the controls. Although controls were matched to cases within two 
weeks of gestational age, the median gestational age of term controls 
was slightly higher than that of cases with late-onset preeclampsia. 
Placental weights were lower in all disease groups compared to controls. 
Birth weights were lower in late-onset preeclampsia than in controls, 
and they tended to be lower in early-onset preeclampsia with or without 
HELLP syndrome than in controls. Early-onset preeclampsia patients 
who were also diagnosed with HELLP syndrome tended to have higher 
systolic blood pressure and to deliver earlier a neonate with lower 
birthweight and placental weight than those patients who had early- 
onset preeclampsia without HELLP syndrome. 
3.2. Proteomic identification of placental proteins 
First, PP1, PP8 and PP22 protein fractions were analyzed using mass 
spectrometry-based proteomics. The name of the identified proteins 
(NCBI, Uniprot), protein identifiers (NCBI, Uniprot), Mascot scores and 
other details are listed in Table 2. PP1 was identified as ‘nicotinate- 
nucleotide pyrophosphorylase’, hereinafter referred to as the protein’s 
short name QPRTase. Twelve peptides were identified covering 59% of 
the sequence of QPRTase. In Suppl. Fig. 1a, the identified peptides are 
shown in red. PP8 was found to be ‘serpin B6’. Sequence coverage of 
‘serpin B6’ was 71% with 31 identified unique peptides (Suppl. Fig. 1b). 
PP22 was identified as ‘protein disulfide-isomerase’. Twenty-five pep-
tides were found and 50% sequence coverage was achieved (Suppl. Fig. 
1c). 
3.3. Gene expression profiles of placental proteins in the human placenta 
compared to other tissues and in villous trophoblasts during differentiation 
Next, we were interested in the placental expression of genes that 
encode PPs. The placenta-specificity score of TFPI2, the gene encoding 
PP5 (tissue factor pathway inhibitor-2, TFPI-2), was 3,304.1 (Fig. 1a). 
TFPI2 also had the highest expression in the placenta, suggesting a 
predominantly placenta-expressed gene. By contrast, genes encoding for 
PP1, PP8, and PP22 had placenta-specificity scores of only 21.6, 1.9, and 
4.4, respectively (Fig. 1a), and their highest tissue expression was not in 
the placenta, showing that these are not predominantly placenta- 
expressed genes. 
To investigate whether these genes are developmentally regulated in 
the placenta, villous trophoblast differentiation-related expression 
changes were determined. We found that the PP5 mRNA level contin-
uously increased from Day 1 until Day 6 of differentiation similar to 
placenta-specific genes [45]. On the contrary, PP1, PP8, and PP22 
mRNA expression levels did not show any increase during differentia-
tion (Fig. 1b). 
3.4. Placental expression of placental proteins in normal placentas 
We then investigated the placental expression pattern of the three 
PPs. The immunostaining of TMAs with specific antibodies, raised 
against PP1, PP8, and PP22, allowed the simultaneous examination of 
these proteins’ expression in 37 placentas. We also immunostained for 
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PP5 as a control for syncytiotrophoblastic protein expression. 
First, we examined the expression pattern of these proteins in 
normal, healthy term placentas. PP1, PP8, and PP22 immunostaining 
was detected primarily in the trophoblasts. The results are as follows: 1) 
Strong PP1 immunostaining was detected in the cytotrophoblasts and 
syncytiotrophoblast, and faint PP1 immunostaining was also detected in 
the villous mesenchymal and endothelial cells. 2) Strong PP8 immuno-
staining was detected in the cytotrophoblasts and syncytiotrophoblast, 
while other cell types of the chorionic villi did not stain for PP8. 3) 
Strong PP22 immunostaining was detected in the cytotrophoblasts and 
syncytiotrophoblast, and faint PP22 immunostaining was also detected 
in the villous mesenchymal and endothelial cells. 4) PP5 immuno-
staining was detected only in the syncytiotrophoblast but not in other 
cell types of the chorionic villi (Fig. 2). 
3.5. Placental expression of placental proteins in preeclampsia and 
HELLP syndrome 
Subsequently, expression patterns of the PPs were investigated in 
placentas taken from cases with preeclampsia and HELLP syndrome 
compared to gestational age-matched controls. Given that PPs are 
mainly expressed by the villous trophoblasts, we evaluated trophoblastic 
Table 2 






















PP1 Q15274 nicotinate-nucleotide 
pyrophosphorylase 
[carboxylating] 
45269149 quinolinate phosphoribosyl- 
transferase 
31,138 1,075 12 59 
PP8 P35237 serpin B6 41152086 serine (or cysteine) proteinase 
inhibitor, clade B 
(ovalbumin), member 6 
42,936 2,227 31 71 
PP22 P07237 protein disulfide-isomerase 20070125 prolyl 4-hydroxylase, beta 
subunit precursor 
57,480 954 25 50  
Fig. 1. Placental and trophoblastic expression of placental proteins. Based on placenta-specificity scores and tissue expression levels, Placental Protein 5 (PP5) is 
predominantly expressed in the placenta, while PP1, PP8, and PP22 are not (a). PP5 mRNA expression level increased from the first day of villous trophoblast 
differentiation, while PP1, PP8, and PP22 mRNA level did not (b). 
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immunoscores. Because PP8 and PP22 immunoscores did not show any 
changes between normal and preeclamptic placentas (data not shown), 
further investigations were focused on only PP1. 
The trophoblastic PP1 immunoscore decreased with gestational age 
as it was lower in term controls compared to preterm controls (mean ±
SE: preterm controls: 2.00 ± 0.11 vs. term controls: 1.63 ± 0.06, p =
0.003) (Figs. 3 and 4). There was increased PP1 immunostaining in late- 
onset preeclampsia (1.98 ± 0.08, p = 0.0008) compared to term controls 
(1.63 ± 0.06) (Figs. 3 and 4). There was no difference in PP1 immu-
noscores between early-onset preeclampsia (1.91 ± 0.09, p = 0.52) and 
Fig. 2. Placental expression of placental 
proteins in normal pregnancies. Strong 
Placental Protein 1 (PP1) immunostaining 
was detected in cytotrophoblasts and the 
syncytiotrophoblast. Faint PP1 immuno-
staining was also detected in villous mesen-
chymal and endothelial cells. Strong PP8 
immunostaining was detected in cyto-
trophoblasts and the syncytiotrophoblast, 
while other cell types of the chorionic villi 
did not stain for PP8. Strong PP22 immu-
nostaining was detected in cytotrophoblasts 
and the syncytiotrophoblast. Faint PP22 
immunostaining was also detected in villous 
mesenchymal and endothelial cells. PP5 
immunostaining was detected only in the 
syncytiotrophoblast but not in other cell 
types of the chorionic villi. No immuno-
staining was detected on negative controls 
(NC). Representative images, hematoxylin 
counterstain, 400 x and 1,000 x magnifica-
tions, scale bar 50 μm and 10 μm. Black ar-
rows depict syncytiotrophoblasts while 
white arrows depict cytotrophoblasts.   
S. Szabo et al.                                                                                                                                                                                                                                   
Placenta 99 (2020) 197–207
203
preterm controls (2.00 ± 0.11) or between early-onset HELLP syndrome 
(2.08 ± 0.1, p = 0.57) and preterm controls (2.00 ± 0.11) (Figs. 3 and 4). 
3.6. The correlation of Placental Protein 1 expression with placental 
weight and birth weight 
The PP1 immunoscores negatively correlated with placental weight 
among controls (R = − 0.54, p = 0.04), but this was not significant 
among patients with preeclampsia (R = − 0.25, p = 0.14). Also, PP1 
immunoscores negatively correlated with birth weight among controls 
(R = − 0.49, p = 0.04), but this was not significant among patients with 
preeclampsia (R = − 0.22, p = 0.16). The PP1 immunoscore did not 
correlate with the MVMP scores of the placenta neither among patients 
with preeclampsia (R = 0.17, p = 0.22) nor among controls (R = 0.07, p 
= 0.4) (Suppl. Table 2). 
4. Discussion 
4.1. Principal findings of this study 
1) PP1, PP8, and PP22 were identified by mass spectrometry as 
‘nicotinate-nucleotide pyrophosphorylase’, ‘serpin B6’ and ‘protein di-
sulfide-isomerase’. 2) Genes encoding PP1, PP8, and PP22 are not pre-
dominantly expressed by the placenta. 3) PP1, PP8, and PP22 mRNA 
expression does not increase during villous trophoblast differentiation. 
4) PP1, PP8, and PP22 proteins are expressed primarily in villous tro-
phoblasts in the placenta. 5) Trophoblastic PP1 immunoscores 
decreased with gestational age. 6) Trophoblastic PP1 immunoscores 
were higher in late-onset preeclampsia compared to term controls. 
4.2. Identification of placental proteins 
We utilized mass spectrometry to identify the uncharacterized 
placental proteins that had been isolated from the human placenta de-
cades ago. 
We identified PP1 as ‘nicotinate-nucleotide pyrophosphorylase’ 
(QPRTase), a key enzyme in the catabolism of quinolinic acid and the 
biosynthesis of NAD(+) in the kynurenine pathway [53], also important 
in tryptophan metabolism in the placenta [54]. QPRTase was described 
in cells of the human central nervous system [55], liver [56], and blood 
[57]. The molecular weight (MW) of PP1 was originally described to be 
160 kDa as a composite of identical subunits by Bohn et al. [35,36]. In 
good accordance, the MW of QPRTase is 180 kDa, and it is a hexamer 
formed by three homodimers. Based on the Uniprot database, a signif-
icant amount of glycans or other post-translational modifications cannot 
be found on QPRTase, which is consistent with the minimal carbohy-
drate content of the PP1 extracted by Bohn et al. [35]. 
We identified PP8 as ‘serpin B6’, a serine protease inhibitor, also 
referred to as a ‘placental thrombin inhibitor’ given its presence in 
placental tissue and its interaction with thrombin [58]. PP8 was 
described as a single-chain protein of 45 kDa that contains 4.1% car-
bohydrate by Bohn et al. [35,36]. In accordance, we found that the 
single-chain ‘serpin B6’ is 43 kDa. 
We identified PP22 as ‘protein disulfide isomerase’, a multifunc-
tional protein that 1) has an important role in the formation of disulfide 
bonds; 2) at high concentrations inhibits aggregation (chaperone 
Fig. 3. Placental expression of Placental Pro-
tein 1 in normal pregnancy and in pre-
eclampsia and HELLP syndrome. Placental 
Protein 1 (PP1) immunostaining was lower in 
term controls (d) compared to preterm controls 
(a). PP1 immunostaining was stronger in late- 
onset preeclampsia (e) compared to term con-
trols (d). PP1 immunostaining was similar be-
tween early-onset preeclampsia with (c) or 
without HELLP syndrome (b) and preterm con-
trols (a). No immunostaining was detected on 
negative controls (f). Representative images, he-
matoxylin counterstain, 400 x magnifications, 
scale bar 50 μm.   
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function); 3) at low concentrations facilitates aggregation (anti-chap-
erone function); 4) is a subunit of different enzymes, like prolyl 4-hy-
droxylase; and 5) is a receptor for galectin-9: the interaction retains 
the protein at the cell surface of Th2 T helper cells, at the plasma 
membrane increases the activity of disulfide reductase and alters redox 
state as well as influences cell migration [59,60]. Using a placental 
cDNA library, earlier PP22 was found to be identical to ‘cellular thyroid 
hormone-binding protein’ by Bohn et al. [35,36]. This is an alternative 
name of ‘protein disulfide-isomerase’; therefore, our study confirms 
former results. PP22 was described as a single-chain protein of 50–65 
kDa without a detectable amount of carbohydrates by Bohn et al. [35]. 
This shows good agreement with the MW of ‘protein disulfide-isomer-
ase’, which is 57 kDa. 
4.3. Placental expression and function of placental proteins in healthy 
conditions 
When analyzing the expression pattern of PPs in the placenta, we 
took into account that, in normal physiologic conditions, there is a 
complex interaction between trophoblasts and other cells, including 
maternal immune cells, that influences the expression of placental 
proteins, and that unique condition is changed after delivering the 
placenta. To better preserve the placental protein expression pattern 
reflecting the normal behavior of placental cells, we completed placental 
sample collection and processing within one half-hour after Cesarean 
delivery in case of all samples according to international standards [50]. 
It was interesting to find that neither of the identified PPs have 
placenta- or trophoblast-specific functions; rather, they are involved in 
general cellular functions. This observation is also reflected by the fact 
that these PPs are not expressed predominantly by the placenta as we 
found in this study. Moreover, this result contrasts with another 
placental protein, PP5/TFPI-2, whose expression occurs predominantly 
in the placenta where it exerts placenta-specific functions in the coag-
ulation cascade. Indeed, quinolinic acid catabolism and NAD(+) 
biosynthesis in the kynurenine pathway, thrombin inhibition in the 
coagulation cascade, and the catalysis of disulfide bond rearrangements 
are processes widely utilized by various cells and tissues in the human 
body. 
Still, the placenta produces large amounts of these PPs as supported 
by past and present RNA/protein evidence; therefore, their functions 
must be pivotal for placental physiology. Indeed, the kynurenine 
pathway is important for fetal development, maternal-fetal immune 
tolerance, and the prevention of placental oxidative stress [59,61–63]; 
thrombin inhibition is critical for placental hemostasis [24]; and chap-
erone functions and redox defense mediated by protein disulfide isom-
erase are critical in placental physiology and defense [10–12,64]. 
It was also interesting to note that these PPs have predominant and 
strong expression in villous trophoblasts; however, we did not find PP1, 
PP8, or PP22 expression to be developmentally regulated in villous 
trophoblasts in contrast to PP5/TFPI-2, which had increasing expression 
during villous trophoblast differentiation. Given that we used a well- 
established in vitro trophoblast culturing and differentiation system 
[16,44–46], we are confident that the detected PP expression patterns 
reflected the trophoblastic developmental program and were only 
minimally affected by the applied in vitro conditions. Overall, this 
finding underscores that these PPs exert their functions, important for all 
villous trophoblastic cells, at various stages of their development. 
Fig. 4. Trophoblastic Placental Protein 1 immu-
noscores. The number of placentas on TMAs and the 
number of immunoscored villi in each study group 
are shown on the first panel (a). Placental Protein 1 
(PP1) immunoscores decreased in term controls 
(1.63 ± 0.06, p = 0.003) compared to preterm con-
trols (2.00 ± 0.11). PP1 immunostaining increased in 
late-onset preeclampsia (1.98 ± 0.08, p = 0.0008) 
compared to term controls (1.63 ± 0.06). PP1 
immunoscores did not change between early-onset 
preeclampsia (1.91 ± 0.09, p = 0.52) and preterm 
controls (2.00 ± 0.11) or between early-onset HELLP 
syndrome (2.08 ± 0.1, p = 0.57) and preterm controls 
(2.00 ± 0.11) (b,c). PE: preeclampsia; HELLP: HELLP 
syndrome; TMA: tissue microarray; *p <0.05, **p 
<0.01.   
S. Szabo et al.                                                                                                                                                                                                                                   
Placenta 99 (2020) 197–207
205
4.4. Placental expression and function of placental proteins in 
preeclampsia and HELLP syndrome 
While examining the potential changes in placental expression of PPs 
in various subsets of preeclampsia and HELLP syndrome, we docu-
mented the up-regulation of PP1 protein quantities in late-onset pre-
eclampsia but not in other preeclampsia subsets when compared to 
gestational age-matched controls. We also did not find any correlation of 
PP1 immunoscores with placental and fetal weight, which are the 
proxies of placental functions. When we combined the early-onset pre-
eclampsia with or without HELLP syndrome groups into one and 
repeated the analyses, there was still no difference between the com-
bined preeclampsia group and preterm controls regarding PP1 immu-
noscores. This substantiates that the lack of difference is a result of 
biological and not statistical reasons. The up-regulation of PP1 only in 
late-onset preeclampsia is a rather interesting finding: similar to other 
investigators, we earlier found gene- or protein-level dysregulations in 
the placenta only in early-onset but not in late-onset preeclampsia, 
which was associated with placental dysfunction. As the placenta is 
severely ill in early-onset preeclampsia, proteins predominantly or 
specifically expressed by the placenta and/or trophoblast are generally 
dysregulated in this disease subset, which is also the case for PP5 [13,16, 
30,31,33,34,44]. However, late-onset preeclampsia is thought to be a 
maternal disease in which the placenta and fetal weights are affected 
less or not at all [7,16,28,65–69]. 
In this context, it is interesting why PP1 expression is up-regulated in 
late-onset preeclampsia. To understand this phenomenon, we need to 
take into account the multi-etiologic nature of preeclampsia and the 
molecular subsets and pathways of preeclampsia that have been iden-
tified by us and others in recent omics and systems biological studies 
[16,70,71]. According to these observations, early-onset preeclampsia is 
mainly associated with placental disease involving the dysregulation of 
trophoblastic functions and gene modules, while late-onset preeclamp-
sia is rather associated with maternal immune and metabolic changes. 
Since PP1/QPRTase is active in the kynurenine pathway involved in 
sustaining placental immune privilege [61,72–75], the dysregulation of 
PP1/QPRTase may be involved in the molecular mechanisms leading to 
a disturbed immune balance at the maternal-fetal interface. In fact, the 
disturbance of the placental kynurenine pathway in preeclampsia has 
been documented by recent studies [73,75] and by other studies con-
nected to inflammatory processes promoting placental dysregulation of 
the kynurenine pathway [54,76]. Nevertheless, our descriptive study 
can only infer an association, and future studies are necessary to 
investigate the functional role of placental PP1/QPRTase in the disease 
pathways of preeclampsia. 
5. Conclusions 
PP1, PP8, and PP22 are expressed primarily in trophoblasts but do 
not have trophoblast-specific regulation or functions. The distinct dys-
regulation of PP1 and PP5 expression in late-onset or early-onset pre-
eclampsia reflects different pathophysiological pathways in these 
preeclampsia subsets. PP5 dysregulation in early-onset preeclampsia is 
associated with placental disease, while PP1 dysregulation in late-onset 
preeclampsia may represent maternal inflammation inducing placental 
functional alterations in late-onset preeclampsia. 
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